Le Lézard
Classified in: Covid-19 virus

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in LifeStance Health Group, Inc. with Losses of $100,000 to Contact the Firm


LOS ANGELES, CA / ACCESSWIRE / August 16, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the federal securities laws.

https://storage.googleapis.com/accesswire/logos/3060.png

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on June 10, 2021 (the "IPO"), are encouraged to contact the firm before October 11, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. LifeStance suffered from a decrease in virtual visits by clients as COVID-19 lockdowns were ending, negatively impacting its out-patient/virtual revenue growth. The Company's operating expenses significantly increased as the number of in-person visits were increasing. The Company lost a significant number of physicians to burn-out, dropping its retention rate below the 87% retention rate touted in the IPO materials. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about LifeStance, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/712065/INVESTOR-ACTION-ALERT-The-Schall-Law-Firm-Encourages-Investors-in-LifeStance-Health-Group-Inc-with-Losses-of-100000-to-Contact-the-Firm


These press releases may also interest you

at 06:30
The "Predictive Vehicle Technology Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global predictive vehicle technology market is expected to grow from $25.35 billion in 2021 to $30.02 billion in 2022 at a...

at 06:25
The "Binders and Scaffolders for Meat And Meat Substitutes Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global binders and scaffolders for meat and meat substitutes market is expected to grow from $3.44...

at 06:15
The "Rehabilitation Robotics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global...

at 06:15
The throat pastilles and cough drop market is expected to grow by USD 1.11 billion during 2021-2026, at a CAGR of 3.61% during the forecast period, according to Technavio. The advantages over other dosage forms, increasing incidences of respiratory...

at 06:15
The "Pet Food Packaging Market By Material Type, By Food Type, By Animals Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to  ResearchAndMarkets.com's offering. The pet food packaging market size was valued...

at 06:10
The "Pneumococcal Vaccines Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal...



News published on 16 august 2022 at 12:30 and distributed by: